View clinical trials related to Nasopharyngeal Cancer Recurrent.
Filter by:This study aims to investigate toripalimab with chemotherapy in participants with nasopharyngeal cancer.
The hypothesis of the study is to address the efficacy and toxicity profile of aforementioned four modalities for rT1-2 NPC. Characters of the patients: - list item one: 168 patients, median age 48 years (range 16-75 years) proven rT1-2 NPC were diagnosed - list item two: Treated with four different irradiation modalities(3D-CRT,IMRT, BT , BT Combined 3D-CRT or IMRT). - list item three: Median time to recurrence was 30 months (range 1-180months). The median follow-up time was 28 months (range, 4-135 months).